Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC)
July 07 2022 - 8:00AM
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology
company developing cellular therapies for chronic, aging-related
and life-threatening conditions, today announced an abstract
regarding the Lomecel-B Phase 2a trial in Alzheimer’s Disease (AD)
has been accepted for a poster presentation at the Alzheimer’s
Association International Conference (AAIC), being held July
31-August 4, 2022 in San Diego, California, as well as virtually.
“We are pleased that the AAIC—the premier organization in AD—has
accepted our poster describing the design of Longeveron’s second
study in Alzheimer’s Disease. Enrollment is currently ongoing in
the Phase 2a trial, and we are excited about the potential of
Lomecel-B as a treatment for this important unmet medical need,”
said Chris Min, M.D., Ph.D., Interim Chief Executive Officer and
Chief Medical Officer.
Earlier this year, Longeveron published a peer-reviewed study of
its Phase 1b Alzheimer's Disease trial in Alzheimer’s &
Dementia® showing that the trial met its primary endpoint,
demonstrating that Lomecel-B was well tolerated in this patient
population.
Details of the poster to be presented at the 2022 AAIC are as
follows:
Title: The Effects of Multiple Doses of
Lomecel-B, Longeveron’ s Cell-based Therapy, on Alzheimer’s
Disease: Study Design and Rationale of this Phase 2a Multi- center
Clinical trial.Format: Poster Presentation
Poster #: 67168Authors: Kevin N.
Ramdas, M.D., M.P.H., Mark Brody, M.D., Brad Herskowitz, M.D., Marc
Agronin, M.D., Jorge G. Ruiz, M.D., Ana Fuquay, Savannah Rodriguez,
Danial Mehranfard, Pharm.D., M.B.A., Lisa McClain-Moss, Dan Gincel,
Ph.D., Joshua M. Hare, M.D. and Anthony A. Oliva Jr.,
PhDDate: Tuesday, August 2, 2022
Time: 12:30 p.m. PT
Information about the Annual AAIC can be found at
https://aaic.alz.org/.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology
company developing cellular therapies for specific aging-related
and life-threatening conditions. The Company’s lead investigational
product is the Lomecel-B™ cell-based therapy product, which is
derived from culture-expanded medicinal signaling cells (MSCs) that
are sourced from bone marrow of young, healthy adult donors.
Longeveron believes that by using the same cells that promote
tissue repair, organ maintenance, and immune system function, it
can develop safe and effective therapies for some of the most
difficult disorders associated with the aging process and other
medical disorders. Longeveron is currently sponsoring Phase 1 and 2
clinical trials in the following indications: Alzheimer’s Disease,
hypoplastic left heart syndrome (HLHS), Aging Frailty, and Acute
Respiratory Distress Syndrome (ARDS). Additional information about
the Company is available at www.longeveron.com.
Investor Contact:
Elsie YauStern IR,
Inc.212-698-8700elsie.yau@sternir.com
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Apr 2023 to Apr 2024